MORGAN STANLEY ASIA PRODUCTS/CALL/SHANGHAI FOSUN PHARMACEUTICAL `H`/21.95/0.02/12.12.24

MORGAN STANLEY ASIA PRODUCTS/CALL/SHANGHAI FOSUN PHARMACEUTICAL `H`/21.95/0.02/12.12.24 Stock

24865

NL0012755821

Market Closed - Hong Kong S.E. 04:00:00 2024-06-11 am EDT
0.013 ^HKD	0.00%

Current year

-55.17%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Chart MORGAN STANLEY ASIA PRODUCTS/CALL/SHANGHAI FOSUN PHARMACEUTICAL `H`/21.95/0.02/12.12.24

Latest news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa	Apr. 26	PR
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs	Dec. 14	PR
Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure	23-08-29	PR
Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa	23-06-06	PR

More news

Quotes 5-day view

Date	Price	Change
24-06-11	0.013	0.00%
24-06-07	0.013	0.00%
24-06-06	0.013	0.00%
24-06-05	0.013	0.00%
24-06-04	0.013	0.00%

Delayed Quote Hong Kong S.E.

Last update June 11, 2024 at 04:00 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Issuer	Morgan Stanley
	24865
ISIN	NL0012755821
Date issued	2022-09-13
Strike	21.95 $
Maturity	2024-12-12 (184 Days)
Parity	50 : 1
Emission price	0.15 $
Emission volume	N/A
Settlement	cash
Currency	HKD

Technical Indicators

Highest since issue	0.232 $
Lowest since issue	0.013 $
Spread	0.003 $
Spread %	23.08%

Company Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities: - research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases; - sale of medical equipments and diagnosis products (17.3%); - medical and hospital services (10.5%); - other (0.1%). China accounts for 72.9% of net sales.

Sector

More about the company

Ratings for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

23.77 CNY

Average target price

28.61 CNY

Spread / Average Target

+20.35%

Consensus